Global Hypogonadism Drug Market Size, Trends and Growth Opportunity, By Therapy (Testosterone Replacement Therapy, Gonadotropin, and Gonadotropin-Releasing Hormones Therapy), By Drug Delivery (Topical Gels, Injectable, Transdermal Patches, Others), By Type (Hypergonadotropic Hypogonadism and Hypogonadotropic Hypogonadism), By Mechanism of Action Type (Steroidal Androgens &Gonadotropins), By Route of Administration (Oral, Injectable, Tropical), By End-Users (Hospitals, Homecare, Specialty Clinics, Others), By Region and forecast till 2030.
Global Hypogonadism Drug Market
Global Hypogonadism Drug Market was valued at USD 9.15 billion in 2022 and is slated to reach USD 12.7 billion by 2030 at a CAGR of 4.5% from 2022-2030.
An insufficient number of hormones are produced by the glands (gonads and ovaries), which results in hypogonadism, a hormonal condition. This hormone is necessary for the operation of several sexual traits. Loss of libido, weakness, infertility, and osteoporosis are all possible symptoms of hypogonadism. The most frequent factor causing hypogonadism is menopause. It often starts around the age of 50 and is normal in all women.
Market Drivers
Hypogonadism may occur more frequently as a result of the rising prevalence of postmenopausal illnesses, fueling market expansion. For instance, the United Nations Economic and Social Commission for Asia-Pacific, a regional agency with offices in Thailand, estimates that in 2021, more than 9% of the population would be women, or more than half of those over 65. This proportion of old women is projected to increase to more than 18% by 2050, or roughly by a factor of two. As postmenopausal disorders are becoming more common, there is an increase in the need for medications to treat hypogonadism because they lower testosterone levels. This element contributes to market expansion. The market is expanding as a result of several government efforts and product approvals. For instance, in 2019, the FDA approved Clarus Therapeutics' Jatenzo testosterone, an oral testosterone replacement treatment used to treat males with primary hypogonadism and hypogonadotropic hypogonadism. In addition, the FDA granted Antares Pharma permission to market Xyosted (testosterone enanthate) Injection in 2018. This contributes to the market's expansion.
Market Restraints
Drugs for hypogonadism have a wide range of side effects. When women use hormone replacement treatment, they may experience local side effects such erratic heartbeat, breast swelling, dryness in the vagina, osteoporosis (weakening of the bones), and other problems. This constraint prevents market growth.
Impact of COVID-19
The pandemic has caused a large number of hypogonadism patients to delay diagnosis and treatment, which has decreased the demand for hypogonadism medications. Demand for hypogonadism medications has decreased as a result of the pandemic's impact on many hypogonadism patients' delays in receiving a diagnosis and treatment. The pandemic's economic effects have caused several nations to cut back on healthcare spending, which has hurt the market for medications treating hypogonadism. Telemedicine has become more widely used as a result of the epidemic, which has decreased the necessity for in-person doctor appointments. The prescription and sales of hypogonadism medications have been impacted by this change.
Market Segmentation
Global Hypogonadism Drug Market is segmented into Therapy, Drug Delivery, Type, Mechanism of Action, Route of Administration, and End User. By Therapy such as Testosterone Replacement Therapy, Gonadotropin, Gonadotropin-Releasing Hormones Therapy. By Drug Delivery such as Topical Gels, Injectable, Transdermal Patches, Others. By Type such as Hypergonadotropic Hypogonadism, Hypogonadotropic Hypogonadism. By Mechanism of Action such as Steroidal Androgens, Gonadotropins. By Route of Administration such as Oral, Injectable, Tropical. By End User such as Hospitals, Homecare, Specialty Clinics, Others.
Regional Analysis
Global Hypogonadism Drug Market is segmented five region Americas, Europe, Asia-Pacific, and the Middle East & Africa. Owing to the rising number of hypogonadism cases and increased public awareness of the hormonal illness, Asia-Pacific is anticipated to experience growth in the hypogonadism medicine market over the forecast period. Furthermore, in the coming years, it is anticipated that the region's market for hypogonadism medications will grow more rapidly due to the increase in the patient population. Due to the rising use of superior, highly advanced products, North America will continue to rule the market during the projection period. The expanding healthcare infrastructure and rising awareness of the hormonal illness with a wide range of treatment choices will both contribute to the growth of the hypogonadism drug market in the region over the course of the forecast period.
Key Players
This report includes a list of numerous Key Players, namely AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceuticals Industries Ltd. (India), Hikma Pharmaceuticals PLC (Japan), Amneal Pharmaceuticals LLC. (U.S.), Alvogen (U.S), Teva Pharmaceutical Industries Ltd (Israel), Endo Pharmaceuticals plc (Ireland), Perrigo Company plc (U.S.), Johnson & Johnson Services, Inc (U.S.).
Market Taxonomy
By Therapy
• Testosterone Replacement Therapy
• Gonadotropin
• Gonadotropin-Releasing Hormones Therapy
By Drug Delivery
• Topical Gels
• Injectable
• Transdermal Patches
• Others
By Type
• Hypergonadotropic Hypogonadism
• Hypogonadotropic Hypogonadism
By Mechanism of Action Type
• Steroidal Androgens
• Gonadotropins
By Route of Administration
• Oral
• Injectable
• Tropical
By End-User
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Europe
o Germany
o France
o UK
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia Pacific
• Middle East & Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest Middle East & Africa
Global Hypogonadism Drug Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Hypogonadism Drug Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing Economic Downturn
4.2.6 Post Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Hypogonadism Drug Market, By Therapy
5.1 Y-o-Y Growth Comparison, By Therapy
5.2 Global Hypogonadism Drug Market Share Analysis, By Therapy
5.3 Global Hypogonadism Drug Market Size and Forecast, By Therapy
5.3.1 Testosterone Replacement Therapy
5.3.2 Gonadotropin
5.3.3 Gonadotropin-Releasing Hormones Therapy
6 Global Hypogonadism Drug Market, By Drug Delivery
6.1 Y-o-Y Growth Comparison, By Drug Delivery
6.2 Global Hypogonadism Drug Market Share Analysis, By Drug Delivery
6.3 Global Hypogonadism Drug Market Size and Forecast, By Drug Delivery
6.3.1 Topical Gels
6.3.2 Injectable
6.3.3 Transdermal Patches
6.3.4 Others
7 Global Hypogonadism Drug Market, By Route of Administration
7.1 Y-o-Y Growth Comparison, By Route of Administration
7.2 Global Hypogonadism Drug Market Share Analysis, By Route of Administration
7.3 Global Hypogonadism Drug Market Size and Forecast, By Route of Administration
7.3.1 Oral
7.3.2 Injectable
7.3.3 Tropical
8 Global Hypogonadism Drug Market, By Type
8.1 Y-O-Y Growth Comparison, By Type
8.2 Global Hypogonadism Drug Market Share Analysis, By Type
8.3 Global Hypogonadism Drug Market Size and Forecast, By Type
8.3.1 Hypergonadotropic Hypogonadism
8.3.2 Hypogonadotropic Hypogonadism
9 Global Hypogonadism Drug Market, By End User
9.1 Y-O-Y Growth Comparison, By End-User
9.2 Global Hypogonadism Drug Market Share Analysis, By End-User
9.3 Global Hypogonadism Drug Market Size and Forecast, By End-User
9.3.1 Hospitals
9.3.2 Homecare
9.3.3 Specialty Clinics
9.3.4 Others
10 Global Hypogonadism Drug Market, By Mechanism of Action Type
10.1 Y-O-Y Growth Comparison, By Mechanism of Action Type
10.2 Global Hypogonadism Drug Market Share Analysis, By Mechanism of Action Type
10.3 Global Hypogonadism Drug Market Size and Forecast, By Mechanism of Action Type
10.3.1 Steroidal Androgens
10.3.2 Gonadotropins
11 Global Hypogonadism Drug Market, By Region
11.1 Global Hypogonadism Drug Market Share Analysis, By Region
11.2 Global Hypogonadism Drug Market Share Analysis, By Region
11.3 Global Hypogonadism Drug Market Size and Forecast, By Region
12 North America Hypogonadism Drug Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 North America Hypogonadism Drug Market Share Analysis, By Therapy
12.3 North America Hypogonadism Drug Market Size and Forecast, By Drug Delivery
12.4 North America Hypogonadism Drug Market Size and Forecast, By Route of Administration
12.5 North America Hypogonadism Drug Market Size and Forecast, By Type
12.6 North America Hypogonadism Drug Market Size and Forecast, By End-Use
12.7 North America Hypogonadism Drug Market Size and Forecast, By Mechanism of Action Type
12.8 North America Hypogonadism Drug Market Size and Forecast, By Country
12.8.1 U.S.
12.8.1.1 Market Size and Forecast, By Therapy
12.8.1.2 Market Size and Forecast, By Drug Delivery
12.8.1.3 Market Size and Forecast, By Route of Administration
12.8.1.4 Market Size and Forecast, By Type
12.8.1.5 Market Size and Forecast, By End-Use
12.8.1.6 Market Size and Forecast, By Mechanism of Action Type
12.8.2 Canada
12.8.2.1 Market Size and Forecast, By Therapy
12.8.2.2 Market Size and Forecast, By Drug Delivery
12.8.2.3 Market Size and Forecast, By Route of Administration
12.8.2.4 Market Size and Forecast, By Type
12.8.2.5 Market Size and Forecast, By End-Use
12.8.2.6 Market Size and Forecast, By Mechanism of Action Type
12.8.3 Mexico
12.8.3.1 Market Size and Forecast, By Therapy
12.8.3.2 Market Size and Forecast, By Drug Delivery
12.8.3.3 Market Size and Forecast, By Route of Administration
12.8.3.4 Market Size and Forecast, By Type
12.8.3.5 Market Size and Forecast, By End-Use
12.8.3.6 Market Size and Forecast, By Mechanism of Action Type
13 Europe Hypogonadism Drug Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Europe Hypogonadism Drug Market Share Analysis, By Therapy
13.3 Europe Hypogonadism Drug Market Size and Forecast, By Drug Delivery
13.4 Europe Hypogonadism Drug Market Size and Forecast, By Route of Administration
13.5 Europe Hypogonadism Drug Market Size and Forecast, By Type
13.6 Europe Hypogonadism Drug Market Size and Forecast, By End-User
13.7 Europe Hypogonadism Drug Market Size and Forecast, By Mechanism of Action Type
13.8 Europe Hypogonadism Drug Market Size and Forecast, By Country
13.8.1 Germany
13.8.1.1 Market Size and Forecast, By Therapy
13.8.1.2 Market Size and Forecast, By Drug Delivery
13.8.1.3 Market Size and Forecast, By Route of Administration
13.8.1.4 Market Size and Forecast, By Type
13.8.1.5 Market Size and Forecast, By End-Use
13.8.1.6 Market Size and Forecast, By Mechanism of Action Type
13.8.2 France
13.8.2.1 Market Size and Forecast, By Therapy
13.8.2.2 Market Size and Forecast, By Drug Delivery
13.8.2.3 Market Size and Forecast, By Route of Administration
13.8.2.4 Market Size and Forecast, By Type
13.8.2.5 Market Size and Forecast, By End-Use
13.8.1.6 Market Size and Forecast, By Mechanism of Action Type
13.8.3 UK
13.8.3.1 Market Size and Forecast, By Therapy
13.8.3.2 Market Size and Forecast, By Drug Delivery
13.8.3.3 Market Size and Forecast, By Route of Administration
13.8.3.4 Market Size and Forecast, By Type
13.8.3.5 Market Size and Forecast, By End-Use
13.8.3.6 Market Size and Forecast, By Mechanism of Action Type
13.8.4 Russia
13.8.4.1 Market Size and Forecast, By Therapy
13.8.4.2 Market Size and Forecast, By Drug Delivery
13.8.4.3 Market Size and Forecast, By Route of Administration
13.8.4.4 Market Size and Forecast, By Type
13.8.4.5 Market Size and Forecast, By End-Use
13.8.4.6 Market Size and Forecast, By Mechanism of Action Type
13.8.5 Italy
13.8.5.1 Market Size and Forecast, By Therapy
13.8.5.2 Market Size and Forecast, By Drug Delivery
13.8.5.3 Market Size and Forecast, By Route of Administration
13.8.5.4 Market Size and Forecast, By Type
13.8.5.5 Market Size and Forecast, By End-Use
13.8.5.6 Market Size and Forecast, By Mechanism of Action Type
13.8.6 Spain
13.8.6.1 Market Size and Forecast, By Therapy
13.8.6.2 Market Size and Forecast, By Drug Delivery
13.8.6.3 Market Size and Forecast, By Route of Administration
13.8.6.4 Market Size and Forecast, By Type
13.8.6.5 Market Size and Forecast, By End-Use
13.8.6.6 Market Size and Forecast, By Mechanism of Action Type
13.8.7 Rest of Europe
13.8.7.1 Market Size and Forecast, By Therapy
13.8.7.2 Market Size and Forecast, By Drug Delivery
13.8.7.3 Market Size and Forecast, By Route of Administration
13.8.7.4 Market Size and Forecast, By Type
13.8.7.5 Market Size and Forecast, By End-Use
13.8.7.6 Market Size and Forecast, By Mechanism of Action Type
14 Asia Pacific Hypogonadism Drug Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Asia Pacific Hypogonadism Drug Market Share Analysis, By Therapy
14.3 Asia Pacific Hypogonadism Drug Market Size and Forecast, By Drug Delivery
14.4 Asia Pacific Hypogonadism Drug Market Size and Forecast, By Route of Administration
14.5 Asia Pacific Hypogonadism Drug Market Size and Forecast, By Type
14.6 Asia Pacific Hypogonadism Drug Market Size and Forecast, By End-User
14.7 Asia Pacific Hypogonadism Drug Market Size and Forecast, By Mechanism of Action Type
14.8 Asia Pacific Hypogonadism Drug Market Size and Forecast, By Country
14.8.1 China
14.8.1.1 Market Size and Forecast, By Therapy
14.8.1.2 Market Size and Forecast, By Drug Delivery
14.8.1.3 Market Size and Forecast, By Route of Administration
14.8.1.4 Market Size and Forecast, By Type
14.8.1.5 Market Size and Forecast, By End-Use
14.8.1.6 Market Size and Forecast, By Mechanism of Action Type
14.8.2 Japan
14.8.2.1 Market Size and Forecast, By Therapy
14.8.2.2 Market Size and Forecast, By Drug Delivery
14.8.2.3 Market Size and Forecast, By Route of Administration
14.8.2.4 Market Size and Forecast, By Type
14.8.2.5 Market Size and Forecast, By End-Use
14.8.2.6 Market Size and Forecast, By Mechanism of Action Type
14.8.3 India
14.8.3.1 Market Size and Forecast, By Therapy
14.8.3.2 Market Size and Forecast, By Drug Delivery
14.8.3.3 Market Size and Forecast, By Route of Administration
14.8.3.4 Market Size and Forecast, By Type
14.8.3.5 Market Size and Forecast, By End-Use
14.8.3.6 Market Size and Forecast, By Mechanism of Action Type
14.8.4 South Korea
14.8.4.1 Market Size and Forecast, By Therapy
14.8.4.2 Market Size and Forecast, By Drug Delivery
14.8.4.3 Market Size and Forecast, By Route of Administration
14.8.4.4 Market Size and Forecast, By Type
14.8.4.5 Market Size and Forecast, By End-Use
14.8.4.6 Market Size and Forecast, By Mechanism of Action Type
14.8.5 Australia
14.8.5.1 Market Size and Forecast, By Therapy
14.8.5.2 Market Size and Forecast, By Drug Delivery
14.8.5.3 Market Size and Forecast, By Route of Administration
14.8.5.4 Market Size and Forecast, By Type
14.8.5.5 Market Size and Forecast, By End-Use
14.8.5.6 Market Size and Forecast, By Mechanism of Action Type
14.8.6 New Zealand
14.8.6.1 Market Size and Forecast, By Therapy
14.8.6.2 Market Size and Forecast, By Drug Delivery
14.8.6.3 Market Size and Forecast, By Route of Administration
14.8.6.4 Market Size and Forecast, By Type
14.8.6.5 Market Size and Forecast, By End-Use
14.8.6.6 Market Size and Forecast, By Mechanism of Action Type
14.8.7 Singapore
14.8.7.1 Market Size and Forecast, By Therapy
14.8.7.2 Market Size and Forecast, By Drug Delivery
14.8.7.3 Market Size and Forecast, By Route of Administration
14.8.7.4 Market Size and Forecast, By Type
14.8.7.5 Market Size and Forecast, By End-Use
14.8.7.6 Market Size and Forecast, By Mechanism of Action Type
14.8.8 Malaysia
14.8.8.1 Market Size and Forecast, By Therapy
14.8.8.2 Market Size and Forecast, By Drug Delivery
14.8.8.3 Market Size and Forecast, By Route of Administration
14.8.8.4 Market Size and Forecast, By Type
14.8.8.5 Market Size and Forecast, By End-Use
14.8.8.6 Market Size and Forecast, By Mechanism of Action Type
14.8.9 Rest of Asia
14.8.9.1 Market Size and Forecast, By Therapy
14.8.9.2 Market Size and Forecast, By Drug Delivery
14.8.9.3 Market Size and Forecast, By Route of Administration
14.8.9.4 Market Size and Forecast, By Type
14.8.9.5 Market Size and Forecast, By End-Use
14.8.9.6 Market Size and Forecast, By Mechanism of Action Type
15 Latin America Hypogonadism Drug Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 Latin America Hypogonadism Drug Market Share Analysis, By Therapy
15.3 Latin America Hypogonadism Drug Market Size and Forecast, By Drug Delivery
15.4 Latin America Hypogonadism Drug Market Size and Forecast, By Route of Administration
15.5 Latin America Hypogonadism Drug Market Size and Forecast, By Type
15.6 Latin America Hypogonadism Drug Market Size and Forecast, By End-User
15.7 Latin America Hypogonadism Drug Market Size and Forecast, By Mechanism of Action Type
15.8 Latin America Hypogonadism Drug Market Size and Forecast, Country
15.8.1. Brazil
15.8.1.1 Market Size and Forecast, By Therapy
15.8.1.2 Market Size and Forecast, By Drug Delivery
15.8.1.3 Market Size and Forecast, By Route of Administration
15.8.1.4 Market Size and Forecast, By Type
15.8.1.5 Market Size and Forecast, By End-Use
15.8.1.6 Market Size and Forecast, By Mechanism of Action Type
15.8.2 Argentina
15.8.1.1 Market Size and Forecast, By Therapy
15.8.1.2 Market Size and Forecast, By Drug Delivery
15.8.1.3 Market Size and Forecast, By Route of Administration
15.8.1.4 Market Size and Forecast, By Type
15.8.1.5 Market Size and Forecast, By End-Use
15.8.1.6 Market Size and Forecast, By Mechanism of Action Type
15.8.3 Colombia
15.8.3.1 Market Size and Forecast, By Therapy
15.8.3.2 Market Size and Forecast, By Drug Delivery
15.8.3.3 Market Size and Forecast, By Route of Administration
15.8.3.4 Market Size and Forecast, By Type
15.8.3.5 Market Size and Forecast, By End-Use
15.8.3.6 Market Size and Forecast, By Mechanism of Action Type
15.8.4 Peru
15.8.4.1 Market Size and Forecast, By Therapy
15.8.4.2 Market Size and Forecast, By Drug Delivery
15.8.4.3 Market Size and Forecast, By Route of Administration
15.8.4.4 Market Size and Forecast, By Type
15.8.4.5 Market Size and Forecast, By End-Use
15.8.4.6 Market Size and Forecast, By Mechanism of Action Type
15.8.5 Chile
15.8.5.1 Market Size and Forecast, By Therapy
15.8.5.2 Market Size and Forecast, By Drug Delivery
15.8.5.3 Market Size and Forecast, By Route of Administration
15.8.5.4 Market Size and Forecast, By Type
15.8.5.5 Market Size and Forecast, By End-Use
15.8.5.6 Market Size and Forecast, By Mechanism of Action Type
15.8.6 Venezuela
15.8.6.1 Market Size and Forecast, By Therapy
15.8.6.2 Market Size and Forecast, By Drug Delivery
15.8.6.3 Market Size and Forecast, By Route of Administration
15.8.6.4 Market Size and Forecast, By Type
15.8.6.5 Market Size and Forecast, By End-Use
15.8.6.6 Market Size and Forecast, By Mechanism of Action Type
15.8.7 Rest of Latin America
15.8.7.1 Market Size and Forecast, By Therapy
15.8.7.2 Market Size and Forecast, By Drug Delivery
15.8.7.3 Market Size and Forecast, By Route of Administration
15.8.7.4 Market Size and Forecast, By Type
15.8.7.5 Market Size and Forecast, By End-Use
15.8.7.6 Market Size and Forecast, By Mechanism of Action Type
16 Middle East Hypogonadism Drug Market Analysis and Forecast (2023-2030)
16.1 Introduction
16.2 Middle East Hypogonadism Drug Market Share Analysis, By Therapy
16.3 Middle East Hypogonadism Drug Market Size and Forecast, By Drug Delivery
16.4 Middle East Hypogonadism Drug Market Size and Forecast, By Route of Administration
16.5 Middle East Hypogonadism Drug Market Size and Forecast, By Type
16.6 Middle East Hypogonadism Drug Market Size and Forecast, By End-User
16.7 Middle East Hypogonadism Drug Market Size and Forecast, By Mechanism of Action Type
16.8 Middle East Hypogonadism Drug Market Size and Forecast, By Country
16.8.1. Saudi Arabia
16.8.1.1 Market Size and Forecast, By Therapy
16.8.1.2 Market Size and Forecast, By Drug Delivery
16.8.1.3 Market Size and Forecast, By Route of Administration
16.8.1.4 Market Size and Forecast, By Type
16.8.1.5 Market Size and Forecast, By End-Use
16.8.1.6 Market Size and Forecast, By Mechanism of Action Type
16.8.2. UAE
16.8.2.1 Market Size and Forecast, By Therapy
16.8.2.2 Market Size and Forecast, By Drug Delivery
16.8.2.3 Market Size and Forecast, By Route of Administration
16.8.2.4 Market Size and Forecast, By Type
16.8.2.5 Market Size and Forecast, By End-Use
16.8.2.6 Market Size and Forecast, By Mechanism of Action Type
16.8.3. Egypt
16.8.2.1 Market Size and Forecast, By Therapy
16.8.2.2 Market Size and Forecast, By Drug Delivery
16.8.2.3 Market Size and Forecast, By Route of Administration
16.8.2.4 Market Size and Forecast, By Type
16.8.2.5 Market Size and Forecast, By End-Use
16.8.2.6 Market Size and Forecast, By Mechanism of Action Type
16.8.4. Kuwait
16.8.4.1 Market Size and Forecast, By Therapy
16.8.4.2 Market Size and Forecast, By Drug Delivery
16.8.4.3 Market Size and Forecast, By Route of Administration
16.8.4.4 Market Size and Forecast, By Type
16.8.4.5 Market Size and Forecast, By End-Use
16.8.4.6 Market Size and Forecast, By Mechanism of Action Type
16.8.5. South Africa
16.8.5.1 Market Size and Forecast, By Therapy
16.8.5.2 Market Size and Forecast, By Drug Delivery
16.8.5.3 Market Size and Forecast, By Route of Administration
16.8.5.4 Market Size and Forecast, By Type
16.8.5.5 Market Size and Forecast, By End-Use
16.8.5.6 Market Size and Forecast, By Mechanism of Action Type
17 Competitive Analysis
17.1 Competition Dashboard
17.2 Market share Analysis of Top Vendors
17.3 Key Development Strategies
18 Company Profiles
18.1 AbbVie Inc. (U.S.)
18.1.1 Overview
18.1.2 Offerings
18.1.3 Key Financials
18.1.4 Business Segment & Geographic Overview
18.1.5 Key Market Developments
18.1.6 Key Strategies
18.2 Bausch Health Companies Inc. (Canada)
18.2.1 Overview
18.2.2 Offerings
18.2.3 Key Financials
18.2.4 Business Segment & Geographic Overview
18.2.5 Key Market Developments
18.2.6 Key Strategies
18.3 Sun Pharmaceuticals Industries Ltd. (India)
18.3.1 Overview
18.3.2 Offerings
18.3.3 Key Financials
18.3.4 Business Segment & Geographic Overview
18.3.5 Key Market Developments
18.3.6 Key Strategies
18.4 Hikma Pharmaceuticals PLC (Japan)
18.4.1 Overview
18.4.2 Offerings
18.4.3 Key Financials
18.4.4 Business Segment & Geographic Overview
18.4.5 Key Market Developments
18.4.6 Key Strategies
18.5 Amneal Pharmaceuticals LLC. (U.S.)
18.5.1 Overview
18.5.2 Offerings
18.5.3 Key Financials
18.5.4 Business Segment & Geographic Overview
18.5.5 Key Market Developments
18.5.6 Key Strategies
18.6 Alvogen (U.S)
18.6.1 Overview
18.6.2 Offerings
18.6.3 Key Financials
18.6.4 Business Segment & Geographic Overview
18.6.5 Key Market Developments
18.6.6 Key Strategies
18.7 Teva Pharmaceutical Industries Ltd (Israel)
18.7.1 Overview
18.7.2 Offerings
18.7.3 Key Financials
18.7.4 Business Segment & Geographic Overview
18.7.5 Key Market Developments
18.7.6 Key Strategies
18.8 Endo Pharmaceuticals plc (Ireland)
18.8.1 Overview
18.8.2 Offerings
18.8.3 Key Financials
18.8.4 Business Segment & Geographic Overview
18.8.5 Key Market Developments
18.8.6 Key Strategies
18.9 Perrigo Company plc (U.S.)
18.9.1 Overview
18.9.2 Offerings
18.9.3 Key Financials
18.9.4 Business Segment & Geographic Overview
18.9.5 Key Market Developments
18.9.6 Key Strategies
18.10 Johnson & Johnson Services, Inc (U.S.)
18.10.1 Overview
18.10.2 Offerings
18.10.3 Key Financials
18.10.4 Business Segment & Geographic Overview
18.10.5 Key Market Developments
18.10.6 Key Strategies
